Armata Pharmaceuticals, Inc. · AMEX:ARMP
Armata Pharmaceuticals — Investor Presentation (January 2021)
23 slides from Armata Pharmaceuticals's investor presentation, Jan 6, 2021
Slide 1: Armata Pharmaceuticals Corporate Presentation, January 6, 2021
Todd Patrick, Chief Executive Officer Brian Varnum, President and Chief Development Officer Steve Martin, Chief Financial Officer January 6, 2021 NYSE American: ARMP
Slide 2: Forward-looking statements
2 I This presentation contains “forward - looking” statements that involve risks, uncertainties and assumptions . If the risks or uncertainties materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward - looking statements . All
Slide 3: Investment Highlights: A Leader in Phage Therapeutics
3 I Pathogen - specific phage cocktails targeting acute/chronic infections of unmet medical need for multiple clinical indications • P. aeruginosa product candidates for respiratory infections – Cystic fibrosis – Non - cystic fibrosis bronchiectasis – Hospitalized pneumonia • S. aureus phage product
Slide 4: Bacteriophages: Natural Predators of Bacteria
4 I Bacteriophages: Natural Predators of Bacteria Phage Progeny Results in Lysis of Targeted Bacteria Source: Prescott Harley Klein’s Microbiology, 7th Ed. • The most ubiquitous organisms on Earth • Bacteria specific, including multi - drug resistant strains • Prior history as therapeutic agent – An
Slide 5: Unmet Need in Antibiotic Resistant Infections
5 I Unmet Need in Antibiotic Resistant Infections Phages May Provide a Powerful Solution to an Urgent Public Health Threat Aug 2019 Xenleta (lefamulin)
Slide 6: Phage as a Novel Therapeutic Modality vs. Classic Antibiotics
6 I Highly specific bactericidal agents will not disrupt microbiome • Lowers risk of infection by Clostridium difficile and vancomycin - resistant enterococci No host toxicities associated with chemical structures • Toxicities associated with antibiotics: kidney, bone marrow, hearing loss… Not an in
Slide 7: Armata Stands on Long History of Phage Development
7 I Armata Stands on Long History of Phage Development M&A Yields Leading Phage Company Biocontrol Ltd. Pre - IND S. aureus and P. aeruginosa phage SGI Asset Acquisition Synthetic phage platform ▪ Pseudomonas program ▪ Pharma partnered program GMP Facility 25 MDR Cases Under EIND Targeted Antimicrob
Slide 8: Armata's Capabilities and Operational Overview
8 I Armata’s Capabilities and Operational Overview Built for Product Development, Bench to Clinic Microbiology Phage Discovery Peptide Chemistry Leads Synthetic Biology Manufacturing & Quality Regulatory • Preclinical biology • Deep formulation expertise • Host cell engineering • Two targeted antimi
Slide 9: Pipeline
9 I Pipeline Program Discovery Preclinical IND - Enabling Phase 1b/2 Partner Pseudomonas aeruginosa Respiratory Infections Staphylococcus aureus CF Bacteremia US DoD * *Department of Defense (Naval Medical Research Center, US Army Medical Research Acquisition Activity, Defense Health Agency) CF: cys
Slide 10: Pseudomonas aeruginosa Program
10 I Pseudomonas aeruginosa Program Cystic Fibrosis Lung Infections Expansion into Non - CF Bronchiectasis Pneumonia
Slide 11: Pseudomonas aeruginosa: Respiratory Opportunity
11 I Cystic Fibrosis • Chronic P.a. infections occur in 55% of CF patients by age 25 – Strongly associated with deteriorating lung function, frequent pulmonary exacerbations, increased mortality • Increased risk of death at 8 years in children with P. aeruginosa infection • Total antibiotic sales in
Slide 12: Phage Products Tailored for P.a. Respiratory Infections
12 I • Distinct phage families • Targets different receptor classes • Cooperative and compatible • Highly potent • Broadly active against clinical isolates • Pursue AP - PA02 in follow - on indication – Inhaled ROA in NCFB; leverages CF trial data • Develop AP - PA03 for pneumonia – Altered composit
Slide 13: Follow-on Studies in CF and Additional Indications
13 I Follow - on Studies in CF Additional Indications Pseudomonas Respiratory Infections Clinical Outline Patient population: Medically stable chronically - infected CF patients Route of administration: Nebulized Goals: Safety and tolerability, pharmacokinetics, dose exploration Efficacy endpoints i
Slide 14: Staphylococcus aureus Program
14 I Staphylococcus aureus Program Bacteremia Expansion into Prosthetic Joint Infection
Slide 15: MRSA: A Serious Threat
15 I Methicillin - Resistant S. aureus (MRSA): A Serious Threat 1 • 323,700 new cases in hospitalized patients • 10,600 deaths • $1.7 billion of attributable healthcare costs First indication: S. aureus bacteremia (SAB) 2 • S. aureus is the most commonly identified pathogen in hospital - and communi
Slide 16: AP-SA02: Phage Product Targeting S. aureus
16 I • Host range coverage of >90% across clinical isolates tested • Robust potency against drug - resistant isolates, including MRSA, VISA, VRSA • Penetrates pre - existing biofilms • Maintains activity in presence of current standard anti - staphylococcal therapy AP - SA02: Phage Product Targeting
Slide 17: AP-SA02: Clinical Outline
17 I Near - term Ph 1b/2 study Follow - on study Follow - on Indication AP - SA02: Clinical Outline $15M in Nondilutive Funding from US DoD to Support Phase 1b/2 Bacteremia Study Patient population: Complicated bacteremia stratified for MRSA Route of administration: I.V. as adjunct to best available
Slide 18: Corporate Summary
18 I Corporate Summary
Slide 19: Strong Global IP Position Through Pending and Issued Patents
19 I Strong Global IP Position Through Pending and Issued Patents 15 Patent Families, Long - Life Patents, Patents Granted in all Major Jurisdictions Expiration dates through 2039 Armata’s patents and applications cover: Therapeutic phage cocktails (Staphylococcus and Pseudomonas) and uses thereof S
Slide 20: Anticipated Topline Milestones 2021/2022
20 I Pseudomonas phage program • Obtain topline data for Phase 1b/2a cystic fibrosis study • Obtain regulatory approval for non - CF bronchiectasis • Obtain regulatory approval for pneumonia Staphylococcus phage program • Obtain clearance from FDA for US IND for bacteremia • Initiate Phase 1b/2a bac
Slide 21: Leadership and Board of Directors
21 I Leadership and Board of Directors Diverse Public Company Drug Development Expertise Management Todd Patrick CEO Mina Pastagia VP, Clinical Development Brian Varnum President and CDO Duane Morris VP, Operations Steve Martin CFO Board of Directors Richard Bastiani Chair Joseph Patti Odysseas Kost
Slide 22: Funding and Capitalization
22 I Cash Position • Completed a $25 million private placement of common stock and warrants with Innoviva, Inc. (NASDAQ: INVA) in March 2020 – Innoviva is a holding company receiving royalties from GSK; $1.4B market capitalization • Armata has cash through mid - 2021 Capitalization • 18.7 million co
Slide 23: Armata Pharmaceuticals
'~ ARMATA PHARMACEUTICALS PURPOSEFUL @ PRECISE ¢ POWERFUL
Armata Pharmaceuticals — Investor Presentation (January 2021) on 6ix